Abstract
Schrodinger Inc. will report its quarterly results on August 05, 2026 Post Market; this preview summarizes consensus revenue, margin, and EPS expectations alongside last quarter’s performance and the prevailing analyst stance through July 29, 2026.
Market Forecast
For the current quarter, the market expects Schrodinger Inc. to post revenue of 47.23 million US dollars, an estimated year-over-year decline of 9.18%, with estimated EBIT of -48.46 million US dollars and estimated EPS of -0.482; year-over-year forecast growth rates indicate improvement in EPS and EBIT despite softer revenue. The company’s own indicated metrics for margin and net profitability are not explicitly guided, though historical gross margins near 50% and net losses suggest investors will watch mix and cost controls for incremental improvement. The software business remains the core revenue engine by mix, and management’s commentary typically emphasizes bookings momentum and renewals for visibility; the drug discovery segment remains milestone- and collaboration-driven, creating quarter-to-quarter variability. The most promising avenue remains software, with last quarter revenue of 35.56 million US dollars and a majority contribution by mix; drug discovery delivered 23.03 million US dollars, and its outlook is tied to partner progress and pipeline catalysts.
Last Quarter Review
In the previous quarter, Schrodinger Inc. reported revenue of 58.59 million US dollars, a gross profit margin of 50.43%, GAAP net loss attributable to the parent of 60.03 million US dollars, a net profit margin of -102.46%, and adjusted EPS of -0.81; revenue declined 1.62% year over year, while adjusted EPS deterioration reflected ongoing investment and revenue mix. Operating performance showed EBIT of -48.79 million US dollars, modestly worse year over year, while revenue exceeded earlier estimates, highlighting stronger-than-expected software contribution and services execution. Main business highlights show software revenue at 35.56 million US dollars (60.70% of total) and drug discovery revenue at 23.03 million US dollars (39.30% of total); software’s steadier renewal base and pricing discipline underpinned the quarter.
Current Quarter Outlook (with major analytical insights)
Software platform as the main business driver
Software, at roughly 61% of last quarter revenue, remains the anchor for Schrodinger Inc.’s model due to recurring licenses, maintenance, and expanding functionality. The forecast revenue deceleration this quarter implies a tougher comparison and potential timing shifts in enterprise renewals, yet the historically resilient gross margin profile suggests the segment could sustain margins near the recent 50% area if discounting is limited and cloud delivery mix stabilizes. Investors should watch commentary on bookings growth, pipeline conversion, and deal size distribution, which together will determine how quickly revenue growth can re-accelerate in the second half. A healthier renewal cadence and uptake of workflow modules can support improved operating leverage even as total revenue trends face near-term headwinds.
Drug discovery collaboration and milestones as the potential upside lever
Drug discovery contributed 23.03 million US dollars last quarter and remains sensitive to partner-driven milestones, R&D project phasing, and option exercises. While management’s revenue outlook embeds variability, positive partner readouts or licensing progress can produce revenue beats even if software growth is muted. The trade-off is expense intensity: higher discovery investment can pressure EBIT and EPS when milestones slip, amplifying quarter-to-quarter volatility. This quarter, the revenue forecast implies limited milestone contributions versus a year ago; any unexpected clinical or preclinical advancements could shift the trajectory, providing optionality to the downside revenue bias.
Key stock price swing factors this quarter
The stock is likely to react most to incremental visibility on software bookings and the shape of second-half renewal cycles. Margin cadence matters: with a recent gross margin near 50% and a negative net margin, investors will scrutinize whether operating costs are pacing to deliver sequential improvement in EBIT and EPS, which the estimates imply year-over-year. Guidance quality and commentary on the timing of larger enterprise agreements can reset expectations, especially given the estimated 9.18% revenue contraction. Any color on collaboration milestones or pipeline catalysts in drug discovery may create asymmetric upside if realized within the quarter, but the base case suggests cautious positioning on that contribution.
Analyst Opinions
Across recent commentary, the balance of views trends cautious, with the majority leaning bearish given the projected revenue decline and continued negative EBIT and EPS prints. Analysts emphasize the near-term headwinds from enterprise deal timing and milestone variability, highlighting that while cost discipline is improving, it may not offset top-line pressure this quarter. Institutions with a cautious stance point to the 9.18% expected revenue drop and an estimated EPS of -0.482 as signals that profitability milestones are still several quarters out; they look for a clearer bookings inflection and steadier discovery contributions before shifting to a more constructive view. The prevailing interpretation is that execution on renewals and visibility into partner milestones will be key to restoring confidence in the growth trajectory over the next two to three quarters.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments